期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

抗高血压新药坎地沙坦研究进展 被引量：16

下载PDF
导出
摘要 介绍了抗高血压新药坎地沙坦的作用机制、药代动力学、药理药效、临床及药物相互作用等。坎地沙坦机制新颖、降压作用强、可与其他降压药联用、不良反应少、临床效果好,极具发展前景。
作者 吕向群
机构地区 浙江省永康市第一人民医院药剂科
出处 《中国药业》 CAS 2005年第5期78-80,共3页 China Pharmaceuticals
关键词 坎地沙坦 血管紧张素Ⅱ受体拮抗剂 高血压 进展
分类号 R972.4 [医药卫生—药品]
  • 相关文献

参考文献20

  • 1刘淑红.血管紧张素Ⅱ阻滞剂伊贝沙坦和坎地沙坦[J].国外医学：药学分册,1998,25(4):246-246.
  • 2郑土才.血管紧张素Ⅱ受体AT_1拮抗剂降血压药物的临床进展及合成[J].化工生产与技术,1998,5(3):41-49. 被引量：2
  • 3张建军.血管紧张素Ⅱ受体拮抗剂研究进展[J].国外医药（抗生素分册）,2001,22(3):134-139. 被引量：13
  • 4Inada R.Rharmacological profiles of candesartan cilexetil(TCV- 116)[J]. Nippon Rinsho 1999, 57(5): 1 130- 1 136.
  • 5Gleiter CH, Morike KF. Clinical pharmacokinetics of candesartan[J]. Clin Pharmacokinet, 2002,41(1):7- 17.
  • 6Shibouta Y, Inada Y, Ojima M, etal. Pharmacological profile of a highly potent and long- acting angiotens in receptor antagonist (TCV- 116)[J]. J Pharmacol ExpTher,1993,266(1):114- 120.
  • 7Hubner R, Hogemann AM, Sunzel M, et al, Pharmacokinetics of candesar- tan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers[J]. J Hum Hypertens,1997,11(supple 2): S19.
  • 8Meineke I, Feltkamp H, Hogemann A, et al. Pharmacokinetics and phar macodynamics of candssartan after adminstration of its pro- drug candesartan cilexetil in patients with mild to moderate essential hypertension- a population analysis[J].Eur J Clin Pharmacol,1997,53(3- 4):221.
  • 9Hoogkamer JF, Kleinbloesem CH, Ouwerkerk M, et al. Pharmarcokinetics and safety of candesartan cilexetil in subjects with normal and impaired liver function[J]. Eur J Clin Pharmacol,1998,54(4):341.
  • 10Inada Y, Ojima M, Kanagawa R, et al, Pharmacologic properties of candesartan cilexetil- possible mechanisms of long- acting antihypertensive action[J].JHum Hypertens,1999,13 (Suppl 1):S75- 80.

二级参考文献30

  • 1[1]Chin HL,Buchan DA. Severe angioedema after long-term use of an angiotensin-converting enzyme inhibitor. [J].Ann Intern Med,1990,112:312
  • 2[2]Sander GE,Mckinnte JJ,Greenberg SS,et al. Angiotensinconverting enzyme inhibitors and angiotensin Ⅱ receptor angagonists in the treatment of heart failure caused by left ventricular systolic dysfunction. [J]. Prog Cardiovasc Dis,1999,41:265
  • 3[3]Johnston CI, Risvanis J. Preclinical pharmacology of angiotensin Ⅱ receptor antagonists: Update and outstanding issues. [J]. Am J Hypertens, 1997,10: 306S
  • 4[4]Mealy N. Elisartan potassium. [J]. Drugs Fut, 1996,21:139
  • 5[5]Ries UJ,Mihm G,Narr B,et al. 6-Substituted benzimidazoles as new nonpeptide biological activity and structureactivity relationship. [J]. J Med Chem, 1993,36: 4040
  • 6[6]Ellingboe JW,Collini MD,Chen J,et al. Metabolites of the angiotensin Ⅱ antagonist tasosartan: The importance of a second acidic group. [J]. J Med Chem, 1998,41: 4251
  • 7[7]Duncia JV,Chiu AT,Carini DJ,et al. The discovery of potent nonpeptide angiotensin Ⅱ receptor blockers: A new class of antihypertensives. [J]. J Med Chem, 1990,33:1312
  • 8[8]Griffiths GJ,Hauck MB,Kohr J,et al. Novel syntheses of 2-butyl-5-chloro-3H-imidazole-4-carbaldehyde: A key intermediate for the synthesis of the angiotensin Ⅱ antagonist losartan. [J]. J Org Chem,1999,64:8084
  • 9[9]Bühlmayer P,Furet P. Valsartan, a potent, orally activeangiotensin Ⅱ antagonist developed from the structurally new amino acid series. [J]. Biorg Med Chem Letters,1994, 4:29
  • 10[10]Bühlmayer P,Ostermayer F, Schmidlin T. Preparation of[(tetrazolylbiphenyl)methyl]amines and analogs as angiotensin Ⅱ antagonists. [P].EP,433983,1991

共引文献23

同被引文献90

引证文献16

二级引证文献35

中国药业
2005年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部